Abstracts tagged "Animal Model"

Abstract Number: 1734 • ACR Convergence 2025
Intra‑articular Liraglutide Halts Osteoarthritis Progression, Surpassing Dexamethasone in Synovial and Cartilage Protection
Coralie Meurot¹, Celine Martin¹, Margot Vieubled², Indira Toillon³, Claire Deldycke¹, Valentine Cheron¹, Soline Trombetta¹, William Sibran¹, Revital Rattenbach¹ and Francis BERENBAUM⁴, ¹⁴P Pharma, Lille, France, ²⁴P Pharma, Lille, ³Sorbonne University, Paris, France, ⁴Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease that cause chronic pain and reduced mobility. Current treatments mainly relieve pain and inflammation, often with corticosteroid…
Abstract Number: 0942 • ACR Convergence 2025
Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
Jennifer Nicholson¹, Maria Ossa-Echeverri¹, Arpitha Haranahalli Shivarudrappa¹, Mark Lusco¹, Maria de la Luz Garcia-Hernandez², John Looney¹, Jennifer Anolik³ and Javier Rangel-Moreno¹, ¹University of Rochester, Rochester, NY, ²University of Rochester, West Henrietta, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Though immune targeted therapies have improved outcomes in lupus nephritis, a significant number of patients experience renal damage and even progression to end stage…
Abstract Number: 0058 • ACR Convergence 2025
Training for increased inflammatory arthritis in mice is not modulated by type 1 interferon
Richard Bell¹, Mary Huang¹, Claire Weigert², Ruoxi Yuan², Toolika Singh², Seda Seren² and Lionel Ivashkiv¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York
Background/Purpose: Disease flares, or episodic escalating inflammation, is a hallmark of autoimmune diseases, like Rheumatoid Arthritis (RA). They are particularly hard to predict and treat…
Abstract Number: 1206 • ACR Convergence 2025
Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Juliane Bremer¹, Judith Nagel², Jana Zschüntzsch³, Kamil K Zajt¹, Tayfun Palaz¹, Thomas Blank⁴, Aylin Ikis¹, Laura A Fischer³, Anna SM Sensmeyer³, Lara Wiechers³, Josef J Reichelt³, Kai P Hofmann⁵, Monika J Wolf⁶, Corinna Leuchtenberger⁷, Priyanka Tripathi¹, Claudia Einer⁸, Hans Zischka², Ulrike Rothermel⁷, Anna L Eck⁷, Regina Reimann⁹, Veronika Kana⁶, Elisabeth Rushing⁶, Adriano Aguzzi⁶, Marco Prinz⁴, David Liebetanz³, Francesca Odoardi³, Chao-Chung Kuo¹, Joachim Weis¹, Florian Kraft¹, Jens Schmidt¹⁰ and Mathias Heikenwälder⁷, ¹University Hospital RWTH Aachen, Aachen, Germany, ²Technical University of Munich, München, Germany, ³University Medical Center Göttingen, Göttingen, Germany, ⁴University of Freiburg, Freiburg, Germany, ⁵DKFZ Heidelberg, Göttingen, Germany, ⁶University Hospital Zürich, Zürich, Switzerland, ⁷DKFZ Heidelberg, Heidelberg, Germany, ⁸Helmholtz Munich, München, Germany, ⁹University Hospital Zürich, Zürich, Germany, ¹⁰Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disorder characterized by inflammation and degeneration with altered proteostasis. To better understand the interrelationship between these…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: 0053 • ACR Convergence 2025
The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model
Jérôme Avouac¹, manon lesturgie², Virginie Gonzalez³, Sujeeba Arulananthan², Anne Cauvet³, Francoise Tilotta⁴ and Yannick Allanore⁵, ¹Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ²INSERM U¹⁰¹⁶, Paris, France, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Université Paris Cité, Montrouge, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: CCN1, a matricellular protein with angiogenic and immunomodulatory properties, is overexpressed in endothelial and synovial tissues of rheumatoid arthritis (RA) patients. Previous findings demonstrated…
Abstract Number: 1191 • ACR Convergence 2025
Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
Alfredo Guzman, Elizabeth Bagley, Rita Spathis, Madison King, Kanneboyina Nagaraju and Melissa Morales, Binghamton University, Johnson City, NY
Background/Purpose: Dysregulation of the ER stress and interferon (IFN) pathways play a major role in the pathophysiology of autoimmune myositis. Upregulation of ER stress markers…
Abstract Number: 0934 • ACR Convergence 2025
The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Arielle Glatman Zaretsky¹, Carley Tasker¹, Pablo Abreu¹, Ciara Torres², Li-Hong Ben¹, Scott MacDonnell¹, Andre Limnander¹ and Jamie Orengo¹, ¹Regeneron, Tarrytown, NY, ²Regeneron, Tarrytown
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease with a prevalence of 1.4-15.13/100,000 adults globally. SLE is highly heterogenous and can involve…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 1003 • ACR Convergence 2025
Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Yan Zhang¹, Brittany Ross¹, Aditi Upadhye¹, Diana Galvan¹, Shaun E Grosskurth¹, Yanjie Bao¹, Romina Riener¹, Annabel Wang¹, Aric Frantz¹, Gregor B Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian I Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
Abstract Number: 0935 • ACR Convergence 2025
Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Brianna Thompson², Vanessa Manada De Lobos² and Carla Marie Cuda³, ¹Northwestern University, Elmhurst, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (anxiety, cognitive dysfunction) lead to the devastating impact of this disease on patients’ health-related quality-of-life. Dysbiosis of gut microbiota…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 1806 • ACR Convergence 2025
Sex differences in knee joint microbial DNA of C57BL/6 mice and the effect of cross-sex microbiome transplantation
Veera Durga Vaishnavi Kurra¹, Ausitn Lopez², Aleksander Szymczak³, Gabriella Dyson³, Pratibha Dube⁴, Padmaja Mehta-d'Souza² and Matlock Jeffries³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Edmond, OK
Background/Purpose: Recent studies have suggested an association between the gut microbiome and osteoarthritis. We have previously shown that the joint microbiome is derived at least…
Abstract Number: 0999 • ACR Convergence 2025
Myositis Induced by Histidyl-Transfer tRNA Synthetase is Exacerbated by Membranopathy and Suppressed by Regulatory T Cells
Samantha Coss¹, Nicholas Young², Shane Bruckner³, Braden Zeno⁴, Gianni Giarrano⁵, Hannah Bulgart⁶, Paula Clemens⁷, Jisna Paul², Chester V. Oddis⁸, noah weisleder⁹, Dana Ascherman⁸ and Wael Jarjour¹⁰, ¹Nationwide Children's Hospital, Columbus, OH, ²Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, ³OSU, Columbus, OH, ⁴Ohio State University, upper arlington, OH, ⁵Division of Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁶Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY, ⁷Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹University of Kentucky, Lexington, KY, ¹⁰The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune disorders targeting muscle as well as extra-muscular organs. Among the most common autoantibodies associated…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…

1
2
3
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].